Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 7 EP applications Richard Charles Sewell has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after December 16, 2012). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP13799318

MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES

IPC classification:
A61K 31/495, A61K 31/496, A61K 31/497, A61K 31/501, A61K 31/506, C07D 241/04, C07D 401/12, C07D 401/14, C07D 403/12, C07D 407/12, C07D 413/12, C07D 413/14, C07D 417/12, C07D 417/14, C07D 471/04
Applicant:
Glaxo Group Limited
Agent:
Richard Charles Sewell, GlaxoSmithKline
Status:
The patent has been granted
EP14855946

NOVEL COMPOUNDS

IPC classification:
C07D 213/75, C07D 257/04, C07D 261/08
Applicant:
GlaxoSmithKline LLC
Agent:
Richard Charles Sewell, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP15800398

NOVEL COMPOUNDS

IPC classification:
A61K 31/495, A61K 31/496, A61P 17/06, A61P 19/00, A61P 37/00, A61P 43/00, C07D 241/04, C07D 403/12
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Richard Charles Sewell, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP15800053

NOVEL COMPOUNDS

IPC classification:
A61K 31/495, A61K 31/496, A61K 31/501, A61K 31/506, A61P 17/06, A61P 37/00, C07D 405/06
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Richard Charles Sewell, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP15726090

1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS

IPC classification:
A61K 31/17, A61P 11/00, A61P 29/00, C07C 211/56, C07C 275/30, C07D 207/10, C07D 211/54, C07D 213/34, C07D 233/64, C07D 239/26, C07D 295/135, C07D 305/06, C07D 307/18, C07D 309/08, C07D 471/04, C07D 487/04
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Richard Charles Sewell, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP15799481

NOVEL COMPOUNDS

IPC classification:
A61K 31/495, A61P 37/02, C07D 403/00
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Richard Charles Sewell, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP17157475

MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES

IPC classification:
A61K 31/495, A61K 31/496, A61K 31/497, A61K 31/501, A61K 31/506, A61P 29/00, A61P 37/00, C07D 241/04, C07D 401/12, C07D 401/14, C07D 403/12, C07D 407/12, C07D 413/12, C07D 413/14, C07D 417/12, C07D 417/14, C07D 471/04
Applicant:
Glaxo Group Limited
Agent:
Richard Charles Sewell, GlaxoSmithKline
Status:
Request for examination was made

Please Sign in to use this feature